SCHEDULE: Ayrton Capital Reports Minor Stake in ReShape Lifesciences
Beneficial Ownership Report
Ayrton Capital LLC, Alto Opportunity Master Fund, and Waqas Khatri reported a combined beneficial ownership of 0.003% in ReShape Lifesciences Inc. common stock.
Summary
- Ayrton Capital LLC, Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri (collectively, the 'Reporting Persons') filed an Amendment No. 1 to Schedule 13G.
- The filing reports beneficial ownership of common stock in ReShape Lifesciences Inc. (Issuer).
- As of June 30, 2025, each Reporting Person beneficially owned 80 shares of the Issuer's common stock.
- This ownership consists of 8 shares of common stock directly held and 72 shares issuable upon the exercise of certain warrants.
- The shares issuable from warrants are subject to a 9.99% beneficial ownership blocker.
- The aggregate beneficial ownership for each Reporting Person represents 0.003% of the Issuer's common stock.
- The percentage is calculated based on 2,385,960 total shares, which includes 1,331,356 shares outstanding as of June 6, 2025, plus 1,054,604 shares sold in a recent offering, in addition to the 72 warrant shares.
- Ayrton Capital LLC serves as the investment manager for Alto Opportunity Master Fund, SPC Segregated Master Portfolio B, and Waqas Khatri is the managing member of Ayrton Capital LLC and a director of the Fund.
Sentiment
Score: 5
Explanation: The filing is a factual report of beneficial ownership, indicating a neutral sentiment. The reported ownership percentage (0.003%) is very small and not indicative of significant positive or negative implications for the company's stock price or operations.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership and does not provide specific insights into broader industry trends or competitive landscape for ReShape Lifesciences Inc. It primarily details an investment firm's minor stake.
Stakeholder Impact
- Shareholders: The filing indicates a very minor, non-influential stake by the reporting persons, unlikely to impact existing shareholders significantly.
Key Dates
| Date | Description |
|---|---|
| 2025-06-06 | Date of 1,331,356 shares outstanding. |
| 2025-06-09 | Date of prospectus supplement on Form 424B5 filed with the SEC, detailing 1,054,604 shares sold in an offering. |
| 2025-06-30 | Date of event which requires filing of this statement and the date as of which holdings are reported. |
| 2025-08-13 | Date of signing of the Schedule 13G Amendment No. 1. |
Keywords
ReShape Lifesciences, Ayrton Capital, Alto Opportunity Master Fund, Waqas Khatri, Beneficial Ownership, Schedule 13G, Common Stock, Warrants, Investment Management, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.